Article Text

Download PDFPDF

5PSQ-138 Impact of high temperature, shaking and light on quality of the therapeutic peptide teduglutide (Revestive) evaluated by LC/MS/MS (Orbitrap) peptide mapping analysis and stress
  1. R Pérez-Robles1,
  2. N Navas2,
  3. S Clemente-Bautista3,
  4. I Jiménez-Lozano3,
  5. MJ Cabañas-Poy3,
  6. J Cabeza4,
  7. A Salmerón-García4
  1. 1Instituto de Investigación Biosanitaria de Granada (FIBAO) – University of Granada, Analytical Chemistry, Granada, Spain
  2. 2University of Granada – Instituto de Investigación Biosanitaria de Granada, Analytical Chemistry, Granada, Spain
  3. 3Vall d’Hebron Hospital, Maternal and Child Pharmacy Service, Barcelona, Spain
  4. 4San Cecilio University Hospital, Department of Clinical Pharmacy, Granada, Spain


Background and importance Teduglutide (Revestive) is a recombinant human GLP-2 analogue indicated in the treatment of short bowel syndrome, a serious and highly disabling condition which results from either loss of portions of intestine or loss of critical intestinal function. A proteinaceous-based medicine, teduglutide is indicated to have low stability, thus the study of the effect of possible in- use mishandling and in- stress conditions are welcome to gain knowledge of its stability and degradation.

Aim and objectives To evaluate the impact on teduglutide’s chemical structure when subjected to in-use mishandling and when it is degraded by the characterisation of its post-translational modifications (PTMs) obtained by liquid chromatography with tandem mass spectrometry (LC/MS/MS) (Orbitrap) peptide mapping analysis after submitting teduglutide samples to 40°C and 60 °C, to smooth shaking and to accelerated light exposition.

Material and methods Samples of reconstituted teduglutide (Revestive) were submitted to 40°C and 60°C (3 hours), to smooth shaking (3 hours) and to accelerated light exposition (24 hours). Tryptic digestion was performed on these samples and the resulted fragments were separated and quantified by LC/MS/MS. BiopharmaFinder 3.1 software (Thermo Scientific) was used for PTMs identification.

Results Different PTMs related to the quality of the medicine were monitored in the primary structure of teduglutide (ie, deamidations, isomerisations and oxidations) [1]. No changes in the PTMs profiles were found in samples subjected to temperature and agitation in comparison to the PTMs profiles of fresh teduglutide. High percentages of oxidations were detected in the samples submitted to light exposition.

Conclusion and relevance The exposition to light modified the PTMs profile of teduglutide inducing oxidations in the primary structure (methionine and tryptophan residues). These might affect teduglutide’s security, efficacy and quality. Therefore, it is highly recommended to protect the drug from light during in-use manipulation. For temperature exposition (40°C and 60°C) and agitation, the PTMs profile was not modified, thus no specific recommendations need be noted in this regard.

References and/or acknowledgements 1. Hmiel LK, et al. Anal Bioanal Chem 2015;407:79–94.

Raquel Pérez-Robles is currently granted a postdoctoral position from the Junta de Andalucía, Spain.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.